Introduction — Inflammation isn’t the problem. Chronicity is.
Inflammation is an essential biological response for survival. It enables the body to react to an insult, repair tissues, contain infection, or heal a lesion. In its acute form, it is rapid, targeted, and then switches off once the threat has been controlled.
So the issue is not inflammation itself, but persistence. When the inflammatory response no longer fully resolves — when it settles into a low-level, “silent” state without dramatic clinical signs — it becomes a driver of systemic biological disorganisation. This is what is referred to as low-grade inflammation. [1,2]
This chronic, silent inflammatory state is now recognised as one of the key biological terrains underlying many modern functional conditions: persistent fatigue, diffuse pain, digestive disruption, metabolic dysregulation, hormonal imbalance and accelerated ageing. [3,4]
I — The biological definition of low-grade inflammation
Low-grade inflammation is characterised by chronic activation of the innate immune system in the absence of acute infection, obvious trauma, or a classic inflammatory disease. [1]
Biologically, it typically involves:
- persistent but moderate production of pro-inflammatory mediators (IL-6, TNF-α, IL-1β) [2,5]
- prolonged activation of macrophages and innate immune cells
- disruption of anti-inflammatory regulatory pathways
- constant interaction with energy metabolism and hormonal signalling
Unlike acute inflammation:
- it is often missed by standard markers
- it is diffuse and systemic
- it acts slowly, but continuously
It is an inflammation of the terrain — not a localised symptom.
II — Low-grade inflammation: a disorder of biological signalling
One common mistake is to view chronic inflammation as an isolated phenomenon. In reality, it reflects a persistent misreading of the environment by the cell. [6]
In low-grade inflammation:
- the cell receives repeated stress signals
- it keeps defence pathways switched on (NF-κB, cytokine signalling)
- it prioritises short-term survival at the expense of repair and performance [5,6]
This context drives:
- increased energy demand
- reduced mitochondrial efficiency
- impaired adaptive capacity
Inflammation becomes a biological background noise — energy-draining and disorganising.
III — The main drivers of silent, chronic inflammation
1) The central role of the gut microbiota
The gut is one of the most powerful regulators of systemic inflammation.
A disrupted microbiota can:
- reduce protective metabolite production
- increase intestinal permeability
- promote the passage of pro-inflammatory compounds into circulation [7,8]
This leads to constant immune stimulation — often referred to as metabolic endotoxaemia — which sustains low-grade inflammation. [8]
2) Food as an inflammatory signal
Beyond calories, food functions as a biological language.
A diet low in fibre and high in rapid sugars, oxidised fats and ultra-processed foods:
- increases glycaemic and insulin spikes
- disrupts the microbiota
- stimulates inflammatory pathways [3,4]
Conversely, a diet built around intact plant matrices, polyphenols and micronutrients supports active anti-inflammatory regulation. [6]
3) Chronic stress and neuro-immune dysregulation
Chronic stress disrupts cortisol dynamics, desynchronises biological rhythms and reshapes immune responses. Over time, it can promote persistent inflammation even in the absence of infectious triggers. [6]
4) Energy metabolism and meta-inflammation
Metabolic overload — particularly abdominal — is directly associated with chronic inflammation. Adipose tissue becomes an active inflammatory organ, releasing cytokines that sustain a state of meta-inflammation. [2,5]
IV — Clinical picture: when inflammation becomes a “terrain”
Low-grade inflammation rarely presents as a single, clear symptom. It acts as a transversal aggravating factor.
It is commonly associated with:
- persistent, non-restorative fatigue
- diffuse aches, stiffness, joint discomfort
- chronic digestive disruption
- hormonal and premenstrual imbalance
- sleep disturbance
- abdominal weight gain
- reduced mental clarity and motivation [3,4]
It can also blunt the response to other therapeutic strategies.
V — Inflammation and ageing: the concept of inflammaging
With age, the body’s ability to regulate inflammation declines. Low-grade inflammation then becomes one of the main engines of biological ageing — a phenomenon known as inflammaging. [2,5]
It contributes to:
- loss of muscle mass
- reduced bone density
- immune fragility
- lower mitochondrial vitality
- declining overall resilience [5,6]
Addressing chronic inflammation is not only about comfort — it is about shifting the trajectory of functional ageing.
VI — A Cellular Nutrition reading: correcting the cellular environment
Cellular Nutrition offers a systemic interpretation: inflammation is a consequence of an unsuitable cellular environment. [6]
The aim is not to “block” inflammation, but to:
- restore the quality of biological signals
- support natural regulatory pathways
- give the cell the resources to exit a constant “alarm” state
This requires coordinated action on:
- the microbiota and intestinal barrier [7,8]
- energy and mitochondrial metabolism [5,6]
- micronutrients involved in immune regulation
- oxidative and inflammatory balance
VII — No. 2 FLAM: the biological logic of the protocol
No. 2 FLAM was designed to fit this terrain-based logic.
It aims to:
- support modulation of the inflammatory response [9–12]
- reinforce immune and neuro-immune balance [10–12]
- protect cellular integrity
- promote a return to a biological state compatible with recovery
FLAM is neither a painkiller nor a symptomatic treatment. It is a regulatory tool, intended to be integrated into a broader Cellular Nutrition strategy.
VIII — Clinical approach: coherence, progressiveness, durability
Managing low-grade inflammation relies on:
- consistency of interventions
- coherent dietary and micronutritional foundations
- attention to stress and lifestyle rhythms
- a medium- to long-term view [6]
This is not a one-off response, but deep terrain work.
IX — Scientific foundations of No. 2 FLAM: academic evidence on the actives
No. 2 FLAM was formulated using actives whose roles in low-grade chronic inflammation are supported by randomised trials, meta-analyses and systematic reviews. [9–17]
1) Turmeric (Curcuma longa) — Curcumin (180 mg)
Curcumin is one of the most extensively studied polyphenols for inflammatory modulation. Clinical data show significant reductions in CRP, IL-6 and TNF-α across various chronic inflammatory contexts. [9–11]
Meta-analyses and umbrella reviews support:
- reduced systemic inflammatory markers
- modulatory effects on NF-κB pathways
- complementary action on oxidative stress [9–11]
2) Boswellia serrata — Resin (240 mg)
Boswellia extracts act notably via leukotriene pathways. Double-blind, placebo-controlled randomised trials report:
- meaningful improvements in pain and function
- reductions in inflammatory markers (including hs-CRP)
- good tolerability with longer use [12–14]
3) Ginseng (Panax ginseng) — Root (100 mg)
Panax ginseng has immunomodulatory and adaptogenic properties. Meta-analyses suggest reductions in IL-6 and TNF-α, with more variable effects on CRP depending on populations. [15–17]
It may also support:
- stress regulation
- neuro-immune signalling
- metabolic resilience
4) Bifidobacterium bifidum — 1 billion CFU
Randomised clinical trials (notably with B. bifidum MIMBb75) show:
- improved digestive symptoms
- improved quality of life
- modulation of intestinal immune responses [18,19]
5) Bifidobacterium longum — 1 billion CFU
Clinical evidence (e.g., B. longum 35624) suggests:
- improved intestinal tolerance
- reduced symptom severity
- inflammatory modulation via the gut–immune axis [20–22]
Overall reading — synergy and coherence in No. 2 FLAM
The value of No. 2 FLAM lies in the coherence of its assembly:
- direct modulation of inflammatory pathways (curcumin, boswellia)
- support for immuno-metabolic resilience (ginseng)
- a structuring action on the gut–immune axis (bifidobacteria) [9–22]
This synergy is fully aligned with a Cellular Nutrition approach.
Conclusion — Reducing inflammatory “noise” to restore resilience
Low-grade inflammation is not inevitable. It is a reversible biological signal — provided its real drivers are addressed. [1–6]
With No. 2 FLAM, the goal is clear: reduce chronic inflammatory noise so the body can recover its capacity for adaptation, recovery and functional longevity.
Bibliography — No. 2 FLAM
Biological foundations & inflammaging
[1] Furman, D., Campisi, J., Verdin, E. et al. (2019) Chronic inflammation in the etiology of disease across the life span. Nature Medicine.
https://www.nature.com/articles/s41591-019-0675-0
https://pubmed.ncbi.nlm.nih.gov/31768008/
[2] Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. and Santoro, A. (2018) Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology.
https://www.nature.com/articles/s41574-018-0059-4
https://pubmed.ncbi.nlm.nih.gov/30104782/
[3] Srour, B., Fezeu, L.K., Kesse-Guyot, E. et al. (2019) Ultra-processed food intake and risk of cardiovascular disease. BMJ.
https://www.bmj.com/content/365/bmj.l1451
https://pubmed.ncbi.nlm.nih.gov/31142457/
[4] Fiolet, T., Srour, B., Sellem, L. et al. (2018) Consumption of ultra-processed foods and cancer risk. BMJ.
https://www.bmj.com/content/360/bmj.k322
https://pubmed.ncbi.nlm.nih.gov/29444771/
[5] Hotamisligil, G.S. (2006) Inflammation and metabolic disorders. Nature.
https://www.nature.com/articles/nature05485
https://pubmed.ncbi.nlm.nih.gov/17167474/
[6] Calder, P.C., Bosco, N., Bourdet-Sicard, R. et al. (2017) Health relevance of the modification of low-grade inflammation in ageing. Clinical Nutrition.
https://www.sciencedirect.com/science/article/pii/S0261561416302444
https://pubmed.ncbi.nlm.nih.gov/27720348/
Gut–inflammation axis
[7] Cani, P.D., Amar, J., Iglesias, M.A. et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes.
https://diabetesjournals.org/diabetes/article/56/7/1761/14056
https://pubmed.ncbi.nlm.nih.gov/17456850/
[8] Bischoff, S.C., Barbara, G., Buurman, W. et al. (2014) Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterology.
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-014-0189-7
https://pubmed.ncbi.nlm.nih.gov/25407511/
Curcumin
[9] Naghsh, N., Sadeghi, A., Rahimi, M. et al. (2023) Effects of curcumin supplementation on inflammatory biomarkers: an umbrella meta-analysis. Frontiers in Nutrition.
https://www.frontiersin.org/articles/10.3389/fnut.2023.1080294/full
https://pubmed.ncbi.nlm.nih.gov/37123999/
[10] Lee, Y.M., Kim, H.J. and Kim, J.H. (2024) Is curcumin intake effective for chronic inflammation? Nutrients.
https://www.mdpi.com/2072-6643/16/11/1728
https://pubmed.ncbi.nlm.nih.gov/38898541/
[11] Kavyani, Z., Musazadeh, V., Faghfouri, A.H. et al. (2024) Effects of curcumin supplementation on inflammatory and oxidative stress markers. Phytotherapy Research.
https://onlinelibrary.wiley.com/doi/full/10.1002/ptr.7981
https://pubmed.ncbi.nlm.nih.gov/38037344/
Boswellia serrata
[12] Sengupta, K., Alluri, K.V., Satish, A.R. et al. (2008) A double-blind, randomized, placebo-controlled study of Boswellia serrata in knee osteoarthritis. Arthritis Research & Therapy.
https://arthritis-research.biomedcentral.com/articles/10.1186/ar2461
https://pubmed.ncbi.nlm.nih.gov/18667054/
[13] Vishal, A.A., Mishra, A., Raychaudhuri, S.P. et al. (2011) A randomized, double-blind, placebo-controlled study of Aflapin® in osteoarthritis. International Journal of Medical Sciences.
https://www.medsci.org/v08p0615.htm
https://pubmed.ncbi.nlm.nih.gov/22022214/
[14] Majeed, M., Majeed, S., Nagabhushanam, K. et al. (2019) Novel Boswellia serrata extract in knee osteoarthritis: a randomized controlled trial. BMC Complementary Medicine and Therapies.
https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-019-2544-0
https://pubmed.ncbi.nlm.nih.gov/30838706/
Ginseng
[15] Mohammadi, H., Karimi, E., Saboori, S. et al. (2019) Effects of ginseng supplementation on inflammatory markers: a systematic review and meta-analysis. Phytotherapy Research.
https://onlinelibrary.wiley.com/doi/full/10.1002/ptr.6402
https://pubmed.ncbi.nlm.nih.gov/31161680/
[16] Saboori, S., Falahi, E., Mohammadi, H. et al. (2019) The effects of ginseng on C-reactive protein levels: a meta-analysis. Complementary Therapies in Medicine.
https://www.sciencedirect.com/science/article/pii/S0965229919300609
https://pubmed.ncbi.nlm.nih.gov/31331589/
[17] Li, Z., Ji, G.E. and Zhang, S. (2023) Ginseng and human health: an umbrella review of meta-analyses. Nutrients.
https://www.mdpi.com/2072-6643/15/9/2156
https://pubmed.ncbi.nlm.nih.gov/37108842/
Probiotics — Bifidobacterium
[18] Guglielmetti, S., Mora, D., Gschwender, M. and Popp, K. (2011) Randomised clinical trial: Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics.
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04643.x
https://pubmed.ncbi.nlm.nih.gov/21418261/
[19] Andresen, V., Gschossmann, J.M. and Layer, P. (2020) Heat-inactivated Bifidobacterium bifidum MIMBb75 in IBS. The Lancet Gastroenterology & Hepatology.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30412-X/fulltext
https://pubmed.ncbi.nlm.nih.gov/32277872/
[20] O’Mahony, L., McCarthy, J., Kelly, P. et al. (2005) Lactobacillus and Bifidobacterium in IBS: symptom modulation and immune effects. Gastroenterology.
https://www.gastrojournal.org/article/S0016-5085(04)01871-5/fulltext
https://pubmed.ncbi.nlm.nih.gov/15765404/
[21] Sabaté, J.M., Jouët, P. and Harnois, F. (2022) Bifidobacterium longum 35624 in irritable bowel syndrome: clinical evidence. Therapeutic Advances in Gastroenterology.
https://journals.sagepub.com/doi/full/10.1177/17562848221080377
https://pubmed.ncbi.nlm.nih.gov/35265116/
[22] Niu, H.L. and Xiao, J.Y. (2020) The efficacy of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Nutrients.
https://www.mdpi.com/2072-6643/12/9/2628
https://pubmed.ncbi.nlm.nih.gov/32899756/